Karol L Thompson

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. doi request reprint Comparison of the diagnostic accuracy of di-22:6-bis(monoacylglycerol)phosphate and other urinary phospholipids for drug-induced phospholipidosis or tissue injury in the rat
    Karol L Thompson
    Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Building 64, Room 2036, Silver Spring, MD 20993, USA
    Int J Toxicol 31:14-24. 2012
  2. doi request reprint Comparison of urinary and serum levels of di-22:6-bis(monoacylglycerol)phosphate as noninvasive biomarkers of phospholipidosis in rats
    Karol L Thompson
    Division of Drug Safety Research, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
    Toxicol Lett 213:285-91. 2012
  3. doi request reprint Using population physiologically based pharmacokinetic modeling to determine optimal sampling times and to interpret biological exposure markers: The example of occupational exposure to styrene
    Marc André Verner
    Institute of Environmental Medicine, Karolinska Institute, Solna 171 77, Sweden
    Toxicol Lett 213:299-304. 2012
  4. pmc Characterization of the effect of sample quality on high density oligonucleotide microarray data using progressively degraded rat liver RNA
    Karol L Thompson
    Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
    BMC Biotechnol 7:57. 2007
  5. doi request reprint Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats
    Karol L Thompson
    Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA
    Cancer Chemother Pharmacol 66:303-14. 2010
  6. doi request reprint Comparison of the diagnostic performance of human whole genome microarrays using mixed-tissue RNA reference samples
    Karol L Thompson
    Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
    Toxicol Lett 186:58-61. 2009
  7. pmc Use of a mixed tissue RNA design for performance assessments on multiple microarray formats
    Karol L Thompson
    Center for Drug Evaluation and Research, US FDA, Silver Spring, MD 20993, USA
    Nucleic Acids Res 33:e187. 2005
  8. ncbi request reprint Evaluation of the Tg.AC assay: specificity testing with three noncarcinogenic pharmaceuticals that induce selected stress gene promoters in vitro and the inhibitory effects of solvent components
    Karol L Thompson
    Division of Applied Pharmacology Research, Office of Testing and Research, Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, Maryland 20708, USA
    Toxicol Sci 74:271-8. 2003
  9. pmc Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium
    Yuzhao Zhou
    Center for Devices and Radiological Health, U S Food and Drug Administration, White Oak Life Sciences Laboratory, Silver Spring, MD 20993, USA
    Toxicol Sci 101:159-70. 2008
  10. pmc An adaptable method using human mixed tissue ratiometric controls for benchmarking performance on gene expression microarrays in clinical laboratories
    P Scott Pine
    Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993 USA
    BMC Biotechnol 11:38. 2011

Detail Information

Publications22

  1. doi request reprint Comparison of the diagnostic accuracy of di-22:6-bis(monoacylglycerol)phosphate and other urinary phospholipids for drug-induced phospholipidosis or tissue injury in the rat
    Karol L Thompson
    Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Building 64, Room 2036, Silver Spring, MD 20993, USA
    Int J Toxicol 31:14-24. 2012
    ..The data provide evidence supporting the use of di-22:6-BMP as a urinary biomarker of PLD in rats...
  2. doi request reprint Comparison of urinary and serum levels of di-22:6-bis(monoacylglycerol)phosphate as noninvasive biomarkers of phospholipidosis in rats
    Karol L Thompson
    Division of Drug Safety Research, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
    Toxicol Lett 213:285-91. 2012
    ..These data help define the potential context-of-use of serum di-22:6-BMP as a non-clinical biomarker of PLD...
  3. doi request reprint Using population physiologically based pharmacokinetic modeling to determine optimal sampling times and to interpret biological exposure markers: The example of occupational exposure to styrene
    Marc André Verner
    Institute of Environmental Medicine, Karolinska Institute, Solna 171 77, Sweden
    Toxicol Lett 213:299-304. 2012
    ..Biomonitoring of chemicals in the workplace provides an integrated characterization of exposure that accounts for uptake through multiple pathways and physiological parameters influencing the toxicokinetics...
  4. pmc Characterization of the effect of sample quality on high density oligonucleotide microarray data using progressively degraded rat liver RNA
    Karol L Thompson
    Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
    BMC Biotechnol 7:57. 2007
    ....
  5. doi request reprint Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats
    Karol L Thompson
    Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA
    Cancer Chemother Pharmacol 66:303-14. 2010
    ..To identify potential additional cardioprotective treatment strategies, we investigated early doxorubicin-induced changes in cardiac gene expression...
  6. doi request reprint Comparison of the diagnostic performance of human whole genome microarrays using mixed-tissue RNA reference samples
    Karol L Thompson
    Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
    Toxicol Lett 186:58-61. 2009
    ....
  7. pmc Use of a mixed tissue RNA design for performance assessments on multiple microarray formats
    Karol L Thompson
    Center for Drug Evaluation and Research, US FDA, Silver Spring, MD 20993, USA
    Nucleic Acids Res 33:e187. 2005
    ..The mixed tissue design produces a reagent with known gene expression changes within a complex sample and can serve as a paradigm for performance standards for microarrays that target other species...
  8. ncbi request reprint Evaluation of the Tg.AC assay: specificity testing with three noncarcinogenic pharmaceuticals that induce selected stress gene promoters in vitro and the inhibitory effects of solvent components
    Karol L Thompson
    Division of Applied Pharmacology Research, Office of Testing and Research, Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, Maryland 20708, USA
    Toxicol Sci 74:271-8. 2003
    ..However, vehicle composition must be carefully selected because the outcome of this assay can be confounded by certain commonly used solvents...
  9. pmc Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium
    Yuzhao Zhou
    Center for Devices and Radiological Health, U S Food and Drug Administration, White Oak Life Sciences Laboratory, Silver Spring, MD 20993, USA
    Toxicol Sci 101:159-70. 2008
    ..Urinary Kim-1 and kidney Kim-1/Havcr1 expression appear to be sensitive and tissue-specific biomarkers that will improve detection of early acute kidney injury following exposure to nephrotoxic chemicals and drugs...
  10. pmc An adaptable method using human mixed tissue ratiometric controls for benchmarking performance on gene expression microarrays in clinical laboratories
    P Scott Pine
    Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993 USA
    BMC Biotechnol 11:38. 2011
    ..To increase the clinical utility of microarrays, assay controls are needed that benchmark performance using metrics that are relevant to the analysis of genomic data generated with biological samples...
  11. pmc The utility of a rodent model in detecting pediatric drug-induced nephrotoxicity
    Parvaneh Espandiari
    Center for Drug Evaluation and Research, Silver Spring, Maryland 20993, USA
    Toxicol Sci 99:637-48. 2007
    ....
  12. pmc Identification of platform-independent gene expression markers of cisplatin nephrotoxicity
    Karol L Thompson
    Center for Drug Evaluation and Research, Division of Applied Pharmacology Research, U S Food and Drug Administration, 10903 New Hampshire Avenue, Life Sciences Building 64, Silver Spring, MD 20993, USA
    Environ Health Perspect 112:488-94. 2004
    ....
  13. ncbi request reprint Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro
    Karol L Thompson
    Division of Applied Pharmacology Research, Office of Testing and Research, Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, Maryland 20708, USA
    Toxicol Sci 74:260-70. 2003
    ..Based on these criteria, amiloride, dipyridamole, and pyrimethamine were selected from 99 rodent noncarcinogens in a drug database for testing the specificity of the Tg.AC assay...
  14. pmc Sources of variation in baseline gene expression levels from toxicogenomics study control animals across multiple laboratories
    Michael J Boedigheimer
    CDER, US FDA, Silver Spring, MD 20993, USA
    BMC Genomics 9:285. 2008
    ....
  15. pmc Improvement in the reproducibility and accuracy of DNA microarray quantification by optimizing hybridization conditions
    Tao Han
    Center for Functional Genomics, National Center for Toxicological Research, US FDA, Jefferson, AR 72079, USA
    BMC Bioinformatics 7:S17. 2006
    ..A successful microarray experiment, however, involves many steps: well-designed oligonucleotide probes, printing, RNA extraction and labeling, hybridization, and imaging. Optimization is essential to generate reliable microarray data...
  16. doi request reprint Quality control of microarray assays for toxicogenomic and in vitro diagnostic applications
    Karol L Thompson
    Division of Applied Pharmacology Research, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland, USA
    Methods Mol Biol 460:45-68. 2008
    ..Regulations and guidelines involved in the application of microarrays as a commercial in vitro diagnostic device are also described...
  17. doi request reprint Kidney injury biomarkers in hypertensive, diabetic, and nephropathy rat models treated with contrast media
    Rodney L Rouse
    Division of Drug Safety Research, Office of Testing and Research, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland, USA
    Toxicol Pathol 41:662-80. 2013
    ..2m, Lcn-2, and BUN were the best predictors of histopathology defined kidney injury...
  18. ncbi request reprint Evaluation of the Tg.AC transgenic mouse assay for testing the human carcinogenic potential of pharmaceuticals--practical pointers, mechanistic clues, and new questions
    Frank D Sistare
    Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, Maryland 20708, USA
    Int J Toxicol 21:65-79. 2002
    ..Data relating to mechanisms of chemical tumor induction in the Tg.AC model are reviewed, and questions have been formulated to encourage research to further guide appropriate future applications of this model...
  19. pmc The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements
    Leming Shi
    National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas 72079, USA
    Nat Biotechnol 24:1151-61. 2006
    ..This study provides a resource that represents an important first step toward establishing a framework for the use of microarrays in clinical and regulatory settings...
  20. pmc Identification of putative gene based markers of renal toxicity
    Rupesh P Amin
    National Institute of Environmental Health Sciences, National Institutes of Health DHHS, Research Triangle Park, North Carolina, USA
    Environ Health Perspect 112:465-79. 2004
    ..We conclude that renal gene expression profiling coupled with analysis of classical end points affords promising opportunities to reveal potential new mechanistic markers of renal toxicity...
  21. ncbi request reprint Analysis of variance components in gene expression data
    James J Chen
    Division of Biometry and Risk Assessment, National Center for Toxicology Research, Food and Drug Administration, Jefferson, AR 72079, USA
    Bioinformatics 20:1436-46. 2004
    ..Finally, we describe the use of variance-component estimates to determine optimal numbers of animals, arrays per animal and sections per array in planning microarray experiments...
  22. ncbi request reprint Normalization methods for analysis of microarray gene-expression data
    Yi Ju Chen
    Division of Biometry and Risk Assessment, National Center for Toxicological Research, Food and Drug Administration, Jefferson, Arkansas 72079, USA
    J Biopharm Stat 13:57-74. 2003
    ..The method that combines a subset approach (median or lowess fit) for location adjustment with a global lowess fit for intensity adjustment appears to perform well...